DE60213596T2 - Abin zum schutz gegen hepatitis - Google Patents

Abin zum schutz gegen hepatitis Download PDF

Info

Publication number
DE60213596T2
DE60213596T2 DE60213596T DE60213596T DE60213596T2 DE 60213596 T2 DE60213596 T2 DE 60213596T2 DE 60213596 T DE60213596 T DE 60213596T DE 60213596 T DE60213596 T DE 60213596T DE 60213596 T2 DE60213596 T2 DE 60213596T2
Authority
DE
Germany
Prior art keywords
tnf
abin
adabin
liver
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60213596T
Other languages
German (de)
English (en)
Other versions
DE60213596D1 (de
Inventor
Rudi Beyaert
Ben Wielockx
Sofie Van Huffel
Filip Delaei
Claude Libert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vlaams Instituut voor Biotechnologie VIB
Original Assignee
Vlaams Instituut voor Biotechnologie VIB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vlaams Instituut voor Biotechnologie VIB filed Critical Vlaams Instituut voor Biotechnologie VIB
Publication of DE60213596D1 publication Critical patent/DE60213596D1/de
Application granted granted Critical
Publication of DE60213596T2 publication Critical patent/DE60213596T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4703—Inhibitors; Suppressors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/168—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Botany (AREA)
  • Toxicology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
DE60213596T 2001-06-22 2002-06-20 Abin zum schutz gegen hepatitis Expired - Lifetime DE60213596T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP01202414 2001-06-22
EP01202414 2001-06-22
PCT/EP2002/007154 WO2003000280A2 (en) 2001-06-22 2002-06-20 Abin-mediated hepatitis protection

Publications (2)

Publication Number Publication Date
DE60213596D1 DE60213596D1 (de) 2006-09-14
DE60213596T2 true DE60213596T2 (de) 2007-09-13

Family

ID=8180525

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60213596T Expired - Lifetime DE60213596T2 (de) 2001-06-22 2002-06-20 Abin zum schutz gegen hepatitis

Country Status (9)

Country Link
US (1) US7094756B2 (https=)
EP (1) EP1397154B1 (https=)
JP (1) JP4252446B2 (https=)
AT (1) ATE334696T1 (https=)
AU (1) AU2002350412B2 (https=)
CA (1) CA2447249A1 (https=)
DE (1) DE60213596T2 (https=)
ES (1) ES2269736T3 (https=)
WO (1) WO2003000280A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003000280A2 (en) 2001-06-22 2003-01-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Abin-mediated hepatitis protection
US20050147608A1 (en) * 2003-05-08 2005-07-07 Beth Israel Deaconess Medical Center, Inc. Novel regulatory mechanisms of NF-kappaB
JP5027508B2 (ja) 2003-09-24 2012-09-19 インスティティ・パスツール ＮＥＭＯオリゴマー化を妨害するように設計されたペプチドによるＮＦ−κＢ活性化の選択的阻害
WO2006029981A1 (en) * 2004-09-13 2006-03-23 Vib Vzw Abin-mediated protection against lung inflammatory disease
EP1871406A1 (en) 2005-04-14 2008-01-02 VIB vzw Treatment of egfr dependent tumors by abin (a20-binding inhibitor of nf kappab)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) * 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) * 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) * 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) * 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) * 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4946787A (en) * 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) * 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5049386A (en) * 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4797368A (en) * 1985-03-15 1989-01-10 The United States Of America As Represented By The Department Of Health And Human Services Adeno-associated virus as eukaryotic expression vector
US4774085A (en) * 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) * 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
WO1991017424A1 (en) 1990-05-03 1991-11-14 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5173414A (en) * 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
US5587308A (en) 1992-06-02 1996-12-24 The United States Of America As Represented By The Department Of Health & Human Services Modified adeno-associated virus vector capable of expression from a novel promoter
UA71889C2 (uk) 1996-04-02 2005-01-17 Йєда Рісерч Енд Дівелопмент Ко. Лтд. Модулятори зв'язаного з рецептором tnf фактора (traf), їх одержання та застосування
AU754434B2 (en) * 1998-05-06 2002-11-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Novel inhibitors of NF-kappaB activation
WO2003000280A2 (en) 2001-06-22 2003-01-03 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Abin-mediated hepatitis protection

Also Published As

Publication number Publication date
US20040136978A1 (en) 2004-07-15
JP2004536827A (ja) 2004-12-09
WO2003000280A2 (en) 2003-01-03
EP1397154B1 (en) 2006-08-02
DE60213596D1 (de) 2006-09-14
EP1397154A2 (en) 2004-03-17
ES2269736T3 (es) 2007-04-01
ATE334696T1 (de) 2006-08-15
WO2003000280A3 (en) 2003-03-20
CA2447249A1 (en) 2003-01-03
US7094756B2 (en) 2006-08-22
AU2002350412B2 (en) 2006-06-15
JP4252446B2 (ja) 2009-04-08

Similar Documents

Publication Publication Date Title
DE69636365T2 (de) Peptide und zusammensetzungen, die die apoptose modulieren.
DE69735939T2 (de) Fhit proteine und nukleinsäuren sowie darauf basierende verfahren
DE69736712T2 (de) Verfahren zur milderung von neuropatischen schmerz mit prosaposin verwandten peptiden
DE69738370T2 (de) Modulatoren des tnf-rezeptor-assoziierten faktors, deren herstellung und verwendungen
DE69736351T2 (de) Methoden und mittel zur hemmung der cdk4-aktivität
EP3530667B1 (en) Peptide having anti-obesity and anti-diabetes efficacy and use thereof
EP1349933A2 (de) Proteine und den proteinen zugrundeliegende dna-sequenzen mit funktion bei entzündungsereignissen
DE60213596T2 (de) Abin zum schutz gegen hepatitis
EP0870024A2 (de) Nukleinsäuresequenzen von genen der high mobility group proteine sowie verwendungen derselben
DE102004031579B4 (de) Peptide zur Inhibition der Interaktion von Proteinkinase A und Proteinkinase A-Ankerproteinen, diese umfassendes Nukleinsäuremolekül, Vektor, Wirtszelle, gegen diese gerichtetes Erkennungsmolekül, diese enthaltende pharmazeutische Zusammensetzung, diese enthaltender Kit und deren Verwendung
DE69929958T2 (de) Modulatoren der funktion von rezeptoren der tnf/ngf rezeptorenfamilie
US20190054137A1 (en) Peptides and methods for treatment of neurodegenerative diseases
DE69806107T2 (de) Methoden und reagenzien zur regulierung von apoptosis
US7297779B2 (en) Colon cancer metastasis inhibitor
US5955579A (en) Islet-specific homeoprotein and transcriptional regulator of insulin gene expression, HOXB13
AU2002350412A1 (en) Abin-mediated hepatitis protection
US20210179680A1 (en) Polypeptide, derivatives thereof, and application thereof in preparation of drugs having resistance to pulmonary fibrosis
EP1631291B1 (en) Use of tyrosine kinase inhibitors to treat diabetes
DE69839150T2 (de) Intrazelluläre glukocortikoid-induzierte leucin-zipper modulatoren von mechanismen des apoptotischen zelltodes
DE60021421T2 (de) APOPTOSE-HEMMENDES POLYPEPTID, FüR DIESES KODIERENDE GENE UND POLYNUKLEOTIDE UND DIESE BEINHALTENDE ZUSAMMENSETZUNGEN
DE69836226T2 (de) Ifn rezeptor 1 bindende proteine, dafür kodierende dna und verfahren zur regulierung der zellulären antwort auf interferone
CN120888648A (zh) Usp18基因作为药物靶标在筛选预防、缓解和/或治疗心肌缺血再灌注损伤的药物中的应用
Samuelsson p57", a glucocorticoid-induced CDK
Samuelsson p57Kip2, a glucocorticoid-induced CDK inhibitor, involved in cell proliferation, apoptosis and differentiation
HK40006566A (en) Peptides having anti-obesity and anti-diabetes effects and use thereof

Legal Events

Date Code Title Description
8364 No opposition during term of opposition